RAPT Stock Summary and Trading Ideas (Rapt Therapeutics | NASDAQ:RAPT)

RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Rapt Therapeutics trades on the NASDAQ stock market under the symbol RAPT.

As of February 4, 2026, RAPT stock price climbed to $57.78 with 5,970,220 million shares trading.

RAPT has a beta of 1.41, meaning it tends to be more sensitive to market movements. RAPT has a correlation of 0.04 to the broad based SPY ETF.

RAPT has a market cap of $1.67 billion. This is considered a Small Cap stock.

In the last 3 years, RAPT traded as high as $251.60 and as low as $5.67.

The top ETF exchange traded funds that RAPT belongs to (by Net Assets): XBI, VTI, IBB, VXF, DWAS.

RAPT has outperformed the market in the last year with a return of +533.6%, while the SPY ETF gained +16.0%. In the last 3 month period, RAPT beat the market returning +96.9%, while SPY returned +0.7%. However, in the most recent 2 weeks RAPT has underperformed the stock market by returning +0.4%, while SPY returned +1.3%.

RAPT support price is $55.03 and resistance is $60.48 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RAPT shares will trade within this expected range on the day.